IP Library Granted Patent US 10,391,223
Granted Patent B2
US 10,391,223 · App. 14/727,403 · Granted Aug 27, 2019

Use of plasmapheresis to treat blood pressure disorders

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,391,223
App. No.
14/727,403
Granted
Aug 27, 2019
Kind
B2
Abstract

A method of treating a blood pressure disorder comprises identifying a patient having a blood pressure disorder, and administering a treatment regime comprising two or more rounds of plasmapheresis to the patient, wherein the treatment regime lowers blood pressure in the patient.

Claims (49)

1. A method of treating primary hypertension, comprising:

identifying a patient having primary hypertension, wherein the patient has a blood pressure and the patient lacks a cholesterol disorder;

identifying that the patient has primary hypertension;

administering a treatment regimen to the patient comprising two or more rounds of plasmapheresis, wherein the two or more rounds comprise a first round of plasmapheresis and one or more subsequent rounds of plasmapheresis, and each subsequent round of plasmapheresis is conducted 5-7 days after the immediately preceding round of the two or more rounds;

administering the first round of plasmapheresis to the patient;

administering a second round of plasmapheresis to the patient 5-7 days after the first round, wherein the second round is a subsequent round of plasmapheresis that immediately precedes the first round; and

lowering the blood pressure of the patient to thereby treat primary hypertension.

2. The method of claim 1 , further comprising identifying that the patient has Stage 1 hypertension or Stage 2 hypertension.

3. The method of claim 1 , wherein the patient has a systolic blood pressure and a diastolic blood pressure, further comprising lowering both the systolic blood pressure and the diastolic blood pressure of the patient.

4. The method of claim 1 , further comprising administering a third round of plasmapheresis to the patient after administering the second round of plasmapheresis, wherein the treatment regimen comprises administering three or more rounds of plasmapheresis to the patient and the third round is a subsequent round.

5. The method of claim 4 , further comprising:

administering a fourth round of plasmapheresis to the patient after administering the third round of plasmapheresis; and

administering a fifth round of plasmapheresis to the patient after administering the fourth round,

wherein the treatment regimen comprises administering five or more rounds of plasmapheresis to the patient, and the fourth round and the fifth round are subsequent rounds.

6. The method of claim 1 , wherein each round of plasmapheresis comprises automated plasmapheresis using a single venipuncture.

7. The method of claim 3 , further comprising lowering the systolic blood pressure by at least 10 mmHg and lowering the diastolic blood pressure by at least 5 mmHg.

8. The method of claim 3 , further comprising lowering the systolic blood pressure by at least 16 mmHg and lowering the diastolic blood pressure by at least 8 mmHg.

9. The method of claim 1 , further comprising:

identifying that the patient has either a systolic blood pressure of at least 140 mmHg or a diastolic blood pressure of at least 90 mmHg; and

identifying that the patient has a systolic blood pressure less than 160 mmHg and a diastolic blood pressure less than 100 mmHg.

10. The method of claim 1 , wherein each round of plasmapheresis comprises automated plasmapheresis using a single venipuncture, wherein the blood of the patient is removed and returned through the same site.

11. A method of treating primary hypertension in a human patient, comprising:

identifying a patient having primary hypertension;

identifying that the patient has stage 1 hypertension;

administering to the patient two or more rounds of plasmapheresis; and

lowering the blood pressure of the patient to thereby treat primary hypertension,

wherein:

each round of plasmapheresis is automated plasmapheresis using a single venipuncture, wherein the blood of the patient is removed and returned through the same site;

stage 1 hypertension is defined as (1) either a systolic blood pressure of at least 140 mmHg or a diastolic blood pressure of at least 90 mmHg, and (2) a systolic blood pressure less than 160 mmHg and a diastolic blood pressure less than 100 mmHg; and

the patient has primary hypertension.

12. The method of claim 11 , wherein the patient has a systolic blood pressure, further comprising lowering the systolic blood pressure of the patient to less than 140 mmHg.

13. The method of claim 11 , wherein each round of plasmapheresis is administered 5 to 9 days after the prior round.

14. The method of claim 11 , wherein the patient lacks a cholesterol disorder.

15. The method of claim 11 , wherein the patient lacks a disease or condition that impairs kidney function.

16. The method of claim 11 , further comprising lowering the systolic blood pressure of the patient to less than 140 mmHg, wherein:

each round of plasmapheresis is administered 5 to 9 days after the prior round; and

the patient lacks a disease or condition that impairs kidney function.

17. A method of treating primary hypertension in a human patient, comprising:

identifying a patient having a systolic blood pressure of at least 140 mmHg or a diastolic blood pressure of at least 90 mmHg;

identifying that the patient has primary hypertension;

administering to the patient two or more rounds of plasmapheresis; and

lowering the blood pressure of the patient to thereby treat primary hypertension,

wherein:

each round of plasmapheresis is automated plasmapheresis using a single venipuncture, wherein the blood of the patient is removed and returned through the same site;

the patient lacks a cholesterol disorder; and

the patient lacks a disease or condition that impairs kidney function.

18. The method of claim 17 , further comprising lowering the systolic blood pressure of the patient to less than 140 mmHg.

19. The method of claim 17 , wherein each round of plasmapheresis is administered 5 to 9 days after the prior round.

20. The method of claim 17 , further comprising identifying that the patient has both (1) either a systolic blood pressure of at least 140 mmHg or a diastolic blood pressure of at least 90 mmHg, and (2) a systolic blood pressure less than 160 mmHg and a diastolic blood pressure less than 100 mmHg.

Assignments (3)
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE NAME FROM GRIFOLS WORLDWIDE WAREHOUSE ANDOPERATIONS LIMITED TO GRIFOLS WORLDWIDE OPERATIONS LIMITED PREVIOUSLY RECORDED ON REEL 038979 FRAME 0981. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Jun 28, 2016
From: GRIFOLS WORLDWIDE WAREHOUSE AND OPERATIONS LIMITED
To: GRIFOLS WORLDWIDE OPERATIONS LIMITED
Reel/Frame 039204/0082 →
ASSIGNEE CHANGE OF ADDRESS Recorded Jun 13, 2016
From: GRIFOLS WORLDWIDE WAREHOUSE AND OPERATIONS LIMITED
To: GRIFOLS WORLDWIDE WAREHOUSE AND OPERATIONS LIMITED
Reel/Frame 038979/0981 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 3, 2015
From: ROSA-BRAY, MARILYN; WADA, SHINJI
To: GRIFOLS WORLDWIDE OPERATIONS LIMITED
Reel/Frame 035779/0444 →